TY - JOUR
T1 - Preclinical pharmacology of neuroleptics
T2 - Focus on new generation compounds
AU - Richelson, Elliott
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - This article reviews the preclinical pharmacology of neuroleptics, with focus on the newer generation compounds: clozapine, risperidone, olanzapine, sertindole, and quetiapine. All of these newer compounds are considered to be atypical neuroleptics, based on certain criteria, which are reviewed. Several hypotheses about the molecular mechanisms that explain atypicality are considered. Finally, the in vitro receptor binding data presented for these and some older compounds are related to the therapeutic and adverse effects of these drugs.
AB - This article reviews the preclinical pharmacology of neuroleptics, with focus on the newer generation compounds: clozapine, risperidone, olanzapine, sertindole, and quetiapine. All of these newer compounds are considered to be atypical neuroleptics, based on certain criteria, which are reviewed. Several hypotheses about the molecular mechanisms that explain atypicality are considered. Finally, the in vitro receptor binding data presented for these and some older compounds are related to the therapeutic and adverse effects of these drugs.
UR - http://www.scopus.com/inward/record.url?scp=10544231051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10544231051&partnerID=8YFLogxK
M3 - Review article
C2 - 8941166
AN - SCOPUS:10544231051
SN - 0160-6689
VL - 57
SP - 4-11+46
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - SUPPL. 11
ER -